<DOC>
	<DOCNO>NCT02086487</DOCNO>
	<brief_summary>whether Nilotinib two sequential dosage form induce quick deep response patient , FISH PB ( Peripheral blood ) would effective way monitor response compare conventional cytogenetics bone marrow ( BM ) sample</brief_summary>
	<brief_title>Efficacy Safety Assessment NIlotinib CML Patients With Suboptimal Response Imatinib Therapy</brief_title>
	<detailed_description>This multicenter , open label trial conduct within Kingdom saudi Arabia CML ( Chronic Myeloid Leukemia ) patient meet eligibility criterion show sub optimal response Imatinib therapy per European leukemia Net ELN 2013 guideline recruit switch Nilotinib 300 mg twice day therapy . Efficacy assessment hematologic cytogenetic response disease progression , perform every 6 month minimum , include hematologic analysis , bone marrow cytogenetics , molecular study ensure nilotinib provide patient respond patient progress could discontinue therapy . Safety assessment include evaluation adverse event , hematologic assessment , biochemical testing , cardiac enzyme assessment , serial electrocardiogram evaluation , physical examination . Adverse event grade accord National Cancer Institute Common Terminology Criteria Adverse Events Version 4.0 . Survival date start nilotinib therapy death cause censor last follow-up patient alive . The data summarize respect demographic baseline characteristic , efficacy evaluation , safety observation measurement .</detailed_description>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Written inform consent prior study procedure perform . 2 . Age 18 male female CML patient chronic phase . 3 . Eastern Cooperative Oncology Group ECOG Performance status 0 , 1 2 4 . Suboptimal response Imatinib therapy determine follow criterion : 4.1 ) Minor cytogenetic response mCyR minimal response 3 month ( Ph+ metaphases BM 35 95 % ) 4.2 ) BCRABL1 transcript &gt; 10 % 3 month ; 4.3 ) Partial cytogenetic response PCyR 6 month ; ( i.e Ph+ metaphase BM 0 35 % ) 4.4 ) BCRABL1 transcript 1 10 % 6 month 4.5 ) Less major molecular response &gt; 12 month ; i.e ( BCRABL1 0.1 1 % ) 5 . Normal serum level potassium , magnesium calcium ≥ LLN ( low limit normal ) correct within normal limit supplement , prior first dose study medication , 6 . Aspartate aminotransferase AST Alanine aminotransferase ALT ≤ 2.5 x ULN ( upper limit normal ) 7 . Alkaline phosphatase ≥ 2.5 x ULN 8 . Total bilirubin ≤ 1.5 x ULN ; 9 . Serum amylase ≤ 1.5 x ULN Performance status ECOG 0,1,2 1 . Previous Exposure Tyrosine Kinase Inhibitor ( TKI ) Imatinib 2 week 2 . Patients already participate clinical trial.Patients compliant Imatinib therapy . 3 . Optimal response Imatinib therapy determine one criterion : 3.1 . CCyR PCyR 3 month ( Ph+ metaphases BM ≤ 35 % ) . 3.2 . BCRABL1 transcript ≤ 10 % 3 month . 3.3 . CCyR 6 month ( Ph+ metaphases BM 0 % ) . 3.4 . BCRABL1 transcript &lt; 1 % 6 month . 3.5 . BCRABL1 transcript ≤ 0.1 % 12 month . 3.6 . BCRABL1 transcript ≤ 0.1 % time . 4 . Failure response Imatinib therapy per ELN guideline 2013 determine criterion : 4.1 . Non complete hematologic response ( Non CHR ) cytogenetic response CyR 3 month ( Ph+ metaphases BM &gt; 95 % ) . 4.2 . Less Partial cytogenetic response PCyR 6 month ( Ph+ metaphases BM &gt; 35 % ) . 4.3 . BCRABL1 transcript &gt; 10 % 6 month . 4.4 . Less complete cytogenetic response CCyR 12 month ( Ph+ metaphases BM &gt; 0 % ) . 4.5 . BCRABL1 transcript &gt; 1 % 12 month . 4.6 . Loss CHR loss CCyR confirm loss MMR* development partially imatinib sensitive BCRABL mutation CCA Ph positive cell time . 5 . Pregnant lactating female 6 . Patients prolong QT interval 7 . Patient history pancreatitis 8 . Previously document T315I mutation ; 9 . Uncontrolled congestive heart failure hypertension ; 10 . Myocardial infarction unstable angina pectoris within past 12 month ; 11 . Significant arrhythmia , include history presence clinically significant ventricular atrial tachyarrhythmias , clinically significant bradycardia , long QT syndrome and/or correct QT interval ( QTc ) &gt; 450 msec screen ECG . Patients complete LBBB ( Left Bundle Branch Block ) ; 12 . Patients concurrently strong CYP3A4 inhibitor . 13 . Other concurrent uncontrolled medical condition ( e.g . uncontrolled diabetes , active uncontrolled infection , acute chronic liver renal disease ) could cause unacceptable safety risk compromise compliance protocol ; 14 . Impaired gastrointestinal function GI disease may alter absorption study drug ( e.g . ulcerative disease , uncontrolled nausea , vomit diarrhea , malabsorption syndrome , small bowel resection gastric bypass surgery ) ; 15 . Patients another primary malignancy currently clinically significant require active intervention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NIlotinib , Suboptimal Response , Imatinib</keyword>
</DOC>